4-chloro-N-(5-chloro-2-(1,2,3,4-tetrahydro-1,5-naphthyridine-1-carbonyl)-pyridine-3-yl)-3-(trifluoromethyl)benzenesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-chloro-N-(5-chloro-2-(1,2,3,4-tetrahydro-1,5-naphthyridine-1-carbonyl)-pyridine-3-yl)-3-(trifluoromethyl)benzenesulfonamide
• 英文别名: 4-chloro-N-[5-chloro-2-(3,4-dihydro-2H-1,5-naphthyridine-1-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide
• 化学式: C₂₁H₁₅Cl₂F₃N₄O₃S
• 分子量: 531.342
• InChiKey: BFWNIYPDYMFNPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢-1,5-萘啶 、 5-chloro-3-(4-chloro-3-(trifluoromethyl)phenyl-sulfonamido)picolinic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 生成 4-chloro-N-(5-chloro-2-(1,2,3,4-tetrahydro-1,5-naphthyridine-1-carbonyl)-pyridine-3-yl)-3-(trifluoromethyl)benzenesulfonamide
  参考文献：
  名称：

  WO2006/76644

  摘要：

  公开号：

文献信息

• Heteroaryl sulfonamides and CCR2
  申请人：Ungashe Solomon

  公开号：US20070037794A1

  公开（公告）日：2007-02-15

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

  提供了化合物作为CCR2受体的强效拮抗剂。动物测试表明这些化合物可用于治疗CCR2的典型疾病——炎症。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR2介导的疾病的方法，以及作为CCR2拮抗剂鉴定的检测控制。
• HETEROARYL SULFONAMIDES AND CCR2
  申请人：Ungashe Solomon

  公开号：US20100056509A1

  公开（公告）日：2010-03-04

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

  提供的化合物作为CCR2受体的有效拮抗剂。动物实验表明，这些化合物对于治疗CCR2的标志性疾病炎症非常有用。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR2介导疾病的方法以及作为鉴定CCR2拮抗剂的检测中的对照。
• Heteroaryl sulfonamides and CCR2/CCR9
  申请人：Ungashe Solomon

  公开号：US20110118248A1

  公开（公告）日：2011-05-19

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

  提供了一些化合物，可以作为CCR2受体的有效拮抗剂。动物实验表明，这些化合物对于治疗CCR2标志性疾病炎症很有用。这些化合物通常是芳基磺酰胺衍生物，并且可用于制药组合物、治疗CCR2介导疾病的方法以及作为CCR2拮抗剂鉴定试验的对照。
• HETEROARYL SULFONAMIDES AND CCR2/CCR9
  申请人：ChemoCentryx, Inc.

  公开号：US20140031348A1

  公开（公告）日：2014-01-30

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

  提供了一些化合物，它们作为CCR2受体的有效拮抗剂。动物实验表明，这些化合物对于治疗CCR2的标志性疾病炎症非常有用。这些化合物通常是芳基磺酰胺衍生物，并且可用于制药组合物、治疗CCR2介导的疾病的方法以及作为CCR2拮抗剂鉴定的测定中的对照物。
• Heteroaryl Sulfonamides and CCR2/CCR9
  申请人：ChemoCentryx, Inc.

  公开号：US20200147066A1

  公开（公告）日：2020-05-14

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.